Completed
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
NCT01239134
- Conditions
- Melanoma, Neoplasm Metastasis, Neoplasms, +14 more
- Locations
-
- Immunotherapeutics Core / Memorial Sloan Kettering Cancer Center New York, United States